福坦替尼作为免疫性血小板减少症二线治疗的有效性
这项3期试验的事后分析比较了福坦替尼作为二线治疗(激素±免疫球蛋白后)与三线及以上治疗(≥2种既往治疗包括二线药物后)的成人免疫性血小板减少症患者。二线组出血事件更少(28% vs 45%)。事后分析提示福坦替尼二线治疗比三线及以上治疗更有效。
要点
- 福坦替尼二线治疗血小板应答率78%,高于三线及以上治疗的48%。
- 二线治疗出血事件发生率28%,低于三线及以上治疗的45%。
- 两组一旦获得应答均倾向于持久,安全性相似。
核心结论
- 事后分析显示福坦替尼作为二线治疗比三线及以上治疗对ITP更有效。
研究设计与样本
- 3期试验的事后分析,比较二线治疗(激素±免疫球蛋白后)与三线及以上治疗(≥2种既往治疗包括二线药物后)的成人ITP患者。
- 二线组32例,三线及以上组113例。
主要发现
- 出血事件:二线组28%,三线及以上组45%。
- 两组一旦获得应答均倾向于持久,安全性特征相似。
关键数值与推荐
- 二线治疗指 after steroids ± immunoglobulins。
- 三线及以上治疗指 after ≥2 prior lines of therapy including a second-line agent。
临床怎么用
- 对于成人ITP患者,福坦替尼可考虑作为二线治疗选择。
局限性
- 为事后分析,非预设主要分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fostamatinib demonstrated efficacy in phase 3 trials of adults with immune thrombocytopenia (ITP). Post hoc analysis compared patients who received fostamatinib as second-line therapy (after steroids ± immunoglobulins) versus third-or-later-line therapy (after ≥2 prior lines of therapy including a second-line agent). Platelet responses ≥50 000/µl were observed in 25/32 (78%) second-line and 54/113 (48%) third-or-later-line patients. Bleeding events were less frequent in second-line (28%) versus third-or-later-line (45%) patients. Responses once achieved tended to be durable in both groups. The safety profile was similar in both groups. In this post hoc analysis, fostamatinib was more effective as second-line than third-or-later-line therapy for ITP.
引用
- Boccia R, Cooper N, Ghanima W, et al. Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia. Br J Haematol. 2020. PMID: 33439486. doi:10.1111/bjh.16959
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。